Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Prevention of acute chest syndrome by implementing a standardized process to improve incentive spirometry use in hospitalized patients with sickle cell disease
source: American Society of Hematology
year: 2017
authors: Omar Niss, Cheri Cole-Jenkins, Blair Davis, Tina Brooks, Katherine Woolery, Teri Fetters, Jennifer Rollins, Patrick T. McGann, Karen Kalinyak
summary/abstract:Acute chest syndrome (ACS) is the second most common cause of admission and the main cause of death in patients with sickle cell disease (SCD). Nearly half of ACS cases develop during hospitalizations. Incentive spirometry (IS) use decreases the incidence of ACS during hospitalization. The 2014 NHLBI guidelines for the management of SCD encouraged the use of incentive spirometry in hospitalized patients to prevent the development of ACS (strong recommendation, moderate-quality evidence). Despite the available evidence and recommendations, IS is underutilized and the use of this simple, inexpensive, and effective intervention in hospitalized patients with SCD is inconsistent. We sought to develop and implement a standardized process to ensure a reliable use of IS in hospitalized patients with SCD and measure its effect on the occurrence of ACS.
Methods: Based on the model for improvement, we implemented a standard process that involved several interventions to improve the use of IS in all hospitalized children and young adults with SCD at Cincinnati Children’s Hospital Medical Center. Interventions included the development of an electronic medical record-based order set to standardize IS orders, supplying inpatient units with incentive spirometers for timely delivery, increasing awareness through education of staff, patients and families, discussing IS use during daily rounds, and standardization of the nursing documentation of IS use. The primary outcome was the percent ACS diagnosis per inpatient encounters per month.
Results: We analyzed all SCD inpatient encounters one year before (April 2015-April 2016; n=224) and one year after (May 2016-May 2017; n=214) the implementation of the new process. The frequency of ACS diagnosis was reduced from 22% (50/224) pre-intervention to 12% (25/214) post-intervention (P=0.002). The median rate of ACS diagnosis per month was reduced from 23% to 12% and this reduction was maintained over one year post intervention. There was an improvement in the reliability of all measurable key processes targeted during this initiative. The percent of inpatient encounters with accurate IS orders increased from 28% to 88% and the percent of encounters with documented actual IS use by the patient improved from 41% pre-intervention to 81% post-intervention. There also was a trend of decreased length of stay from an average of 3.3 days in the 12 months preceding intervention to an average of 3.1 days in the year following the implementation of the new process. Possibly due to increased awareness for ACS among the clinical staff, there also was an unintended increase in the number of chest radiographs (CXR) performed from 16% pre-intervention (35 total CXR) to 37% post- intervention (70 total CXR). Despite this increase in the number of CXR performed, the diagnosis of ACS was still decreased by nearly half.
organization: Cincinnati Children's Hospital, Cincinnati, OHread more
+myBinderRelated Content
-
Fetal Haemoglobin in Sickle-cell Disease: From Genetic Epidemiology to New Therapeutic StrategiesSickle-cell disease affects millions of ...
-
The Upside of Bad GenesFor the last two decades, they’ve had ...
-
Hydroxycarbamide for Children With Sickle Cell Disease (SCD)Hydroxycarbamide is a medicine taken by ...
-
Bioverativ and Sangamo announce FDA acceptance of IND application for gene-edited cell therapy BIVV003 to treat sick...Bioverativ Inc., a Sanofi company dedi...
-
Matthew Porteus awarded grant for sickle cell anemia workThe California Institute for Regenerativ...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
Sickle Cell Retinopathyhttps://www.youtube.com/watch?v=tCgAHWvV...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.